Radionuclides used for oncology applications must emit radiation with a relatively short path length to maximize impact on cancer cells while minimizing effects on healthy tissue two main types of radiation used in targeted radionuclide therapy are alpha particles and beta particles.
Radiopharmaceuticals consist of a radionuclide and a targeting molecule that delivers a sufficient level of radiation to disease sites. Martin Pomper, M.D., Ph.D., director of nuclear medicine and molecular imaging at Johns Hopkins and Michael Zalutsky, Ph.D., professor of radiology, at the Duke University School of Medicine are co-inventors of the astatine-211-labeled targeted alpha therapy. PMI is developing this astatine-211-labeled inhibitor of PSMA as PMI21 and expects to initiate clinical trials in the first half of next year. (PMI), a clinical-stage company developing targeted radiopharmaceuticals and theranostics for patients with cancer, today announced it has executed a licensing agreement with Johns Hopkins University for exclusive rights to an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA) which is typically elevated in prostate cancer cells. GAITHERSBURG, Md., December 21, 2021-( BUSINESS WIRE)-Precision Molecular, Inc. Currently in IND-enabling studies, PMI21 is expected to advance into clinical trials in patients with metastatic prostate cancer in 2022Īstatine-211 labelling offers important advantages in terms of potency and safety of radiopharmaceuticals as compared to other radionuclides
0 kommentar(er)
